|
|
UK participating companies - Download brochure here |
|---|---|
A4P Consulting |
A4PBio provide expert resource and services for the management and oversight of outsourcing of bioanalysis and bio-logistics for the life science sector.
We are a client-focused, flexible, company with considerable drug development experience and knowledge formed within Pharmaceutical, Biotechnology and CRO organisations, this allows us to provide value added, cost effective, scientifically robust and regulatory compliant solutions covering small/large molecules and genomics. Our bio-logistics group provide flexible, cost effective and scalable solutions in the selection and oversight of global providers for pro-actively managed transport of time and temperature critical biological samples, cell-based therapies and materials.
|
Aigenpulse |
Aigenpulse is a state-of-the-art software platform focused on accelerating drug discovery and development by using advanced data technologies and machine learning to address three key data problem areas – re-use, efficiency and quality. Researchers use the platform to structure, share and analyse their research data and to scale repetitive tasks, eliminating the frustrations of dealing with Big Data & expediting discovery and development of better targets and candidates. Our mission is to combine machine learning and human expertise to facilitate the efficient creation of better drugs; making them available to more people.
|
Almac Diagnostic Services |
Almac Diagnostic Services is a stratified medicine company specialising in biomarker driven clinical trials. Our global laboratories offer tailored diagnostic solutions from biomarker discovery, assay development & validation, to CDx development & commercialisation.
Almac offer an optimised dual DNA and RNA extraction protocol to enable extensive, or focused, biomarker identification from a single FFPE tumour sample, saving precious tissue, time and cost. In addition, our innovative data driven Bioinformatics solutions enable high quality data output from challenging sample types. Almac has developed a unique powerful reporting solution for RNA projects utilising the Hallmarks of Cancer called claraT.
|
Bioclavis |
BioClavis leverages the proprietary TempO-Seq® transcriptomic/genomic platform technology (developed by BioSpyder) for analysing large sets of thousands to tens of thousands of samples on customizable biomarker panels of tens to thousands of genes simultaneously. Our internal R&D programs are focused on biomarker discovery and validation; and we perform contract services for screening applications in partnership with therapeutic developers, chemical companies, and researchers. In particular, low input requirements and efficient high throughput processing facilitates multi-parameter genetic readout (and QA/QC) of advanced in vitro culture systems, iPSC-derived models, and 3D organoids.
|
Biorelate |
Biorelate curates knowledge to help advance the world’s most promising biomedical innovations. Galactic AI™ is our cognitive computing platform. It ensures researchers are working from the best understanding of all of the existing scientific data locked away in text. Galactic AI™ supports: systematic review, causal interaction data, market intelligence, and data science for target validation.
|
C4x Discovery |
C4X Discovery uses cutting-edge proprietary technologies to design and create best-in-class small-molecule drug candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry and completed its first deal last year. Its innovative DNA-based target identification platform (Taxonomy3®) utilises human genetic datasets to identify novel patient-specific drug targets. This is complemented by its sophisticated drug design platform Conformetrix that utilises 4D molecular ligand analyses to provide new and unprecedented insight into the behaviour of drug molecules, enabling the production of novel, potent and selective compounds more effectively.
|
Cohesion Medical |
COHESION® is an award-winning Digital Health company and solutions provider to NHS Scotland. Our open interoperable technologies connect our go-anywhere Personal Health Wallet and cloud-based Integrated Clinical Care platform with real-time data analytics for population health modelling and precision medicine insights. COHESION® has recently won two Innovate UK Innovation Awards for its Cancer Early Detection And Risk (CEDAR) system and its big data-driven Precision Medicine Platform for Inflammatory Diseases. Our solutions improve patient experience, healthcare efficiency and intervention efficacy while accelerating research understanding and new medicines discovery.
|
Eagle Genomics
|
We are a B2B company, building a cloud-based enterprise platform to enable the digital reinvention of Life Sciences R&D in sectors such as pharmaceuticals, personal care, cosmetics and agritech/food. |
FarmaTrust
|
FarmaTrust is a blockchain and AI solutions company for the pharmaceutical and healthcare industry. We track products and treatments utilising blockchain to ensure data integrity, records are immutable and incorruptible. This trusted data is then used for deep data analysis and AI services. Ultimately our data services will inform clients of what they should produce, when they should produce it, in what quantities for which territories.
|
Fios Genomics |
Fios Genomic provide bioinformatics data analysis to pharmaceutical and biotechnological companies, CROs and academia. We help in drug discovery & development and applied research across all species.
We can analyse all types of ‘omics data along with other outputs such as imaging data, clinical information & FACS analysis. The final outcome of our analysis projects is a unique data report file that comes as a secure website link where all methods, references, QC results and final outcome are fully described. The reports are bespoke and offer clear visualisations of what the data hold about patients, the disease or drug of interest.
|
MicroMatrices |
MicroMatrices leverage proprietary technologies to obtain mechanistic/phenotypic data from human relevant 3D cell cultures and other tissues. We use three complementary platforms throughout the drug discovery process: target identification, compound discovery and optimization, in vitro and in vivo safety assessment, personalised medicine:
SpheroMatrices® (www.spheromatrices.com) proprietary spheroid tissue microarray for multiplexed 3D culture analytics;
Integrated Transcriptomic & Proteomic Profiling for pathways and translation assessment;
Pathology Guided Image Analysis: Visualisation/quantification of drug targets/biomarkers, bespoke IA algorithms.
|
OracleBio |
A leading digital pathology services CRO with in-depth expertise in quantitative histopathology techniques to support Pharmaceutical R&D. With extensive experience of quantifying immune cell numbers, biomarker expression and therapeutic proof of mechanism read-outs within pre-clinical and clinical tissue, we deliver detailed cell-by-cell data for improved decision making within R&D. OracleBio uses AI image analysis approaches to extract quantitative data from histopathology samples, delivering reproducible data applicable to statistical analysis. In the field of immuno-oncology, our multiplex data can be used to quantify the action of therapies on the invasion, activation and spatial distribution of immune cells within tumour tissue.
|
Pangaea Data AI |
Pangaea is optimising drug discovery and development processes through easy identification of patient cohorts, who are required for finding new drug targets (precision medicine) and to run clinical trials. Pangaea's software product uses machine learning to automatically label patient records from electronic health record systems (EHRs) with metadata such as ICD, SNOMED and HPO terms, which are used for identifying patient cohorts. This machine learning driven automation ensures consistency between the metadata and the clinical characteristics (symptoms) noted in a patient's record, which allows researchers to identify suitable patients in significantly less time and with higher accuracy.
|
Reprocell |
REPROCELL is a leading ‘human tissue and data company’ providing services to pharmaceutical and biotechnology companies. At its core is the ability to ethically-source fresh and frozen human biospecimens from patients. In combination with its range of laboratory services and its extensive database, such patient-derived material and predictive tests of drug responses in living tissue allows clients to better understand their medicines prior to clinical trials.
|
RowAnalytics |
RowAnalytics has built a world-leading multi-omic analytics platform to reveal the genetic basis of disease. We find and validate novel targets/candidates with detailed genetic explanations of function, high drugability and more accurate stratification biomarkers. We analyze huge genomic, phenotypic and clinical datasets. Our precisionlife platform is orders of magnitude faster and creates deeper understanding of patient stratification than traditional methods. We’re using our unique insights to build a pipeline in neuropsychiatric and cardiometabolic diseases. We’ll develop a few tractable candidates to clinical phase, out-license other assets to biopharma companies, and identify patients who will respond positively to existing/new therapies.
|
